Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Status:
Unknown status
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is
being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line
therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).